Last reviewed · How we verify

bortezomib, dexamethasone, thalidomide, and cyclophosphamide

Millennium Pharmaceuticals, Inc. · Phase 2 active Small molecule

bortezomib, dexamethasone, thalidomide, and cyclophosphamide is a Small molecule drug developed by Millennium Pharmaceuticals, Inc.. It is currently in Phase 2 development.

At a glance

Generic namebortezomib, dexamethasone, thalidomide, and cyclophosphamide
SponsorMillennium Pharmaceuticals, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about bortezomib, dexamethasone, thalidomide, and cyclophosphamide

What is bortezomib, dexamethasone, thalidomide, and cyclophosphamide?

bortezomib, dexamethasone, thalidomide, and cyclophosphamide is a Small molecule drug developed by Millennium Pharmaceuticals, Inc..

Who makes bortezomib, dexamethasone, thalidomide, and cyclophosphamide?

bortezomib, dexamethasone, thalidomide, and cyclophosphamide is developed by Millennium Pharmaceuticals, Inc. (see full Millennium Pharmaceuticals, Inc. pipeline at /company/millennium-pharmaceuticals-inc).

What development phase is bortezomib, dexamethasone, thalidomide, and cyclophosphamide in?

bortezomib, dexamethasone, thalidomide, and cyclophosphamide is in Phase 2.

Related